Investor Relations

Latest Financial Results

Q3 2021

Quarter Ended Sep 30, 2021

Company Overview

Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.

Investor Contact Information


Lucid Diagnostics Inc.
One Grand Central
60 East 42nd Street, Suite 4600
New York, NY 10165
T: 212-949-4319

Investor Relations

Lisa DeScenza
T: 617-351-0243

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place
New York, NY 10004